DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA455776
Title:
A Novel Therapy System for the Treatment of Occult Prostate Cancer
Descriptive Note:
Annual rept. 1 Apr 2005-31 Mar 2006
Corporate Author:
CINCINNATI UNIV OH
Report Date:
2006-05-01
Pagination or Media Count:
10.0
Abstract:
The goal of this research was to investigate efficacy and mechanisms of H5BVIFN- , a novel immunotherapeutic agent, against prostate cancer in animal models. The objectives in year 2 were to determine efficacy of a mixture of irradiated TRAMP-L5 mouse prostate cancer cells and lyophilized H5BVIFN- in regressing orthotopic tumors of TRAMP-L5 cells and to study effects of intratumoral injection of H5BVIFN- on expression of immune stimulatory cytokine in tumors. We found that subcutaneous injections of irradiated TRAMP-L5 cells, recombinant IFN- , or H5BVIFN- , partially inhibited orthotopic growth of TRAMP-L5 cells in syngeneic mice. An additive inhibitory effect was observed in mice injected with a mixture of irradiated TRAMP-L5 cells and H5BVIFN- . However, none of the therapies was able to eradicate orthotopic tumors. Intratumoral delivery of H5BVIFN- was not able to enhance expression of immunestimulatory cytokines interleukin IL-2, IL-12, or interferon-Y.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
